April 24, 2018 / 12:23 AM / a month ago

BRIEF-FDA Advisory Committee Recommends Approval Of Baricitinib 2Mg, Not 4Mg

April 23 (Reuters) - Incyte Corp:

* FDA ADVISORY COMMITTEE RECOMMENDS THE APPROVAL OF BARICITINIB 2MG, BUT NOT 4MG, FOR THE TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS

* U.S. FDA ADVISORY COMMITTEE DID NOT RECOMMEND APPROVAL OF 4-MG DOSE OF BARICITINIB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below